ProfileGDS5678 / 1438449_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 68% 68% 65% 69% 73% 73% 69% 70% 66% 70% 67% 69% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.3881570
GSM967853U87-EV human glioblastoma xenograft - Control 24.2149968
GSM967854U87-EV human glioblastoma xenograft - Control 34.2047468
GSM967855U87-EV human glioblastoma xenograft - Control 43.8675165
GSM967856U87-EV human glioblastoma xenograft - Control 54.2458269
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5812473
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.6418673
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.297269
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3983170
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.964966
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.399870
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0962767
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.2300469
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.2692569